Buy this biopharmaceutical stock that can rally 25%, says RBC Capital Markets
Insmed’s bronchiectasis treatment in development offers an opportunity for investors, according to RBC Capital Markets. Analyst Leonid Timashev initiated coverage of the biopharmaceutical stock at an outperform rating. Timashev set a $100 price target, which suggests upside of 25% over where the stock finished Monday. “While shares have continued to do well in the face…